MedTrace Logo

Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer

NCT03567655 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-06-26

No results posted yet for this study

Summary

This registry aims to evaluate the efficacy of using high-dose oral progestin in young women with stage I endometrial adenocarcinoma with grade 2 differentiation or superficial myometrial invasion as a fertility-sparing management.

Conditions

Interventions

DRUG

Farlutal tab. 500mg/ Pfizer

Medroxyprogesterone Acetate

Sponsors & Collaborators

  • Korean Gynecologic Oncology Group

    collaborator OTHER

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Yong-Man Kim, MD Ph.D. · Korean Gynecologic Oncologic Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-15
Primary Completion
2022-10-31
Completion
2022-11-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03567655 on ClinicalTrials.gov